Innovative Cancer Immunotherapy Targeting Macrophages and T Cells ID: 2015-066

This technology represents a novel approach in cancer treatment by specifically targeting cancer cells through engineered immune cells without harming healthy tissue.

Technology Overview

The technology focuses on the development of advanced cancer immunotherapies using engineered Chimeric Antigen Receptors (CARs) and Bispecific T-cell Engagers (BiTEs) that target Hypoxanthine-Guanine Phosphoribosyltransferase (HGPRT) on cancer cells. It encompasses modifying leukocytes, including macrophages and T-cells, to express receptors against HGPRT, enabling targeted destruction of tumor cells and promoting a robust anti-tumor immune response.

Key Advantages

• High specificity in targeting cancer cells while sparing healthy tissues
• Utilization of the body's immune system to fight cancer, reducing the need for traditional chemotherapy and its side effects
• Engineering of both macrophages and T-cells provides a dual approach to cancer immunotherapy
• Potential to overcome resistance to other forms of cancer therapy

Problems Addressed

• Minimization of damage to healthy cells during cancer treatment
• Overcoming the limitations of current cancer immunotherapies by targeting a novel and specific marker on cancer cells
• Improvement of the efficacy of cancer immunotherapy through advanced engineering of immune cells
• Addressing the challenge of tumor-induced immunosuppression and tumor microenvironment that supports cancer growth

Additional Information

Technology ID: 2015-066
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025